MedTrace Logo

516-BOTOX Urinary Incontinence Detrusor

NCT00850733 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2009-09-17

No results posted yet for this study

Summary

The specific aim of this study is to evaluate the safety and efficacy of each of 2 dosages of BOTOX® (200 U or 300 U) compared to placebo injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have not been adequately managed with anticholinergic therapy.

Conditions

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Veterans Medical Research Foundation

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-09-30
Completion
2009-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00850733 on ClinicalTrials.gov